Developer docs
API playgroundTry for free, no card

Search company profiles

Biocat

Full company profile

uuid000y3sv

Namestring
Biocat
Legal namestring
Biocat, la Fundació BioRegió de Catalunya
Websiteurl
biocat.cat
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Biocat (legal name: Biocat, la Fundació BioRegió de Catalunya) is a public-private foundation established in 2006 at the initiative of the Government of Catalonia and Barcelona City Council, headquartered at the Parc Científic de Barcelona. It functions as the official cluster coordinator for Catalonia's life sciences and healthcare innovation ecosystem — known as the BioRegion of Catalonia — rather than as a product company. Biocat does not develop proprietary technology products; instead, its core activity is orchestrating innovation across the ecosystem through a portfolio of interconnected programs and digital platforms, including acceleration programs (CRAASH Barcelona, ATMP Catalyst), training programs (d·HEALTH Barcelona), the Health Investment Portal connecting startups with investors, the PASS program for healthcare system adoption, the ATMP Catalonia advanced therapies hub, and the European PRECISEU project on personalized medicine. It also publishes the annual BioRegion Report, the authoritative intelligence source for the sector.

Biocat serves five primary stakeholder segments: startups and spin-offs in biotech, medtech, digital health, and advanced therapies; research institutions and universities; domestic and international investors and corporate venture arms (e.g., Ysios, Asabys, Novartis, Roche, Sanofi, Werfen); the Catalan Health System (SISCAT) through CatSalut, AQuAS, and the Ministry of Health; and large corporates seeking partnership and licensing opportunities. All core programs and services are provided free of charge to participants, with operations funded through institutional grants, public funding programs, and trustee support. Governance is shared: the Board of Trustees includes ministers from the Government of Catalonia alongside representatives from pharmaceutical companies, industry associations (Farmaindustria, Fenin Catalunya, Catalonia.Health), research institutions, and venture capital firms, with the President of the Government of Catalonia serving as Chairman.

The organization has approximately 11–50 employees led by CEO Robert Fabregat and a director team covering strategy, marketing, finance, acceleration, and scale-up. Its reach extends across 1,650 companies, 94 research institutions, 464 active startups, and 80+ investment firms operating in the BioRegion, with the broader sector representing 7.6% of Catalonia's GDP, €48.691 billion in turnover, and €9.165 billion in healthcare exports (45.7% of Spain's national total).

Short descriptiontext

Biocat is the public-private foundation coordinating Catalonia's life sciences and healthcare innovation ecosystem, serving startups, research institutions, investors, corporates, and the Catalan Health System through acceleration programs, investment matching platforms, and adoption programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare innovation ecosystem, life sciences acceleration, biotech investment matchmaking, cluster management services, health system innovation adoption
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Life Sciences Innovation Ecosystem Coordination
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Institutional / Public Funding
TypeManaged Services
Description

Biocat operates as a public-private foundation established in 2006 at the initiative of the Government of Catalonia and Barcelona City Council. It is funded through institutional grants, public funding programs, and membership/support from private-sector trustees. The foundation does not charge for its core programs and services.

biocat.cat
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ATMP Catalonia
Description

The Advanced Therapies Hub of Catalonia, coordinated by Biocat, which drives research, manufacturing and development of advanced and emerging therapies to position Catalonia as a global benchmark hub.

biocat.cat
+3 more records
Core offering1 text field

Biocat is a public-private foundation that coordinates the life sciences and healthcare innovation ecosystem of Catalonia by running acceleration programs (CRAASH Barcelona, d·HEALTH Barcelona, ATMP Catalyst), investment matchmaking via the Health Investment Portal, healthcare-system adoption programs (PASS, INNOPASS), the ATMP Catalonia advanced-therapies hub, European project coordination (PRECISEU), and ecosystem intelligence (BioRegion of Catalonia Report). All programs and services are offered free of charge to entrepreneurs, researchers, investors, corporates, and the Catalan Health System.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • €517 million in startup and scaleup investment raised in 2025, a historic record (+43% vs. 2024)
+3 more records
Product overview1 text field

Biocat functions as a public-private foundation that coordinates and accelerates the life sciences and healthcare innovation ecosystem in Catalonia, rather than as a single product company. Its offering consists of multiple interconnected programs and platforms: acceleration programs (CRAASH Barcelona, d·HEALTH Barcelona, ATMP Catalyst) that support entrepreneurs and researchers; the Health Investment Portal connecting startups with investors; the ATMP Catalonia hub for advanced therapies; and the PASS (Catalan Health System Innovation Access Program) comprising an Innovation Platform, Tools and Programs Navigator, and Support Unit to facilitate healthcare innovation adoption. Additionally, Biocat coordinates European projects like PRECISEU and publishes the BioRegion of Catalonia Report as the official intelligence source for the ecosystem. The programs and platforms work together to support the full innovation lifecycle from research to market adoption and investment.

Product and service14 records
1CRAASH Barcelona
CategoryAcceleration Program
Description

A three-month acceleration program (currently in its 9th edition) that validates and brings to market innovations in medical devices, diagnostics, and digital health. Targeted at research teams and entrepreneurs established in or linked to Catalonia with high-potential projects.

2d·HEALTH Barcelona
CategoryTraining Program
Description

A training program (currently in its 11th edition) that provides tools to learn how to innovate and develop a business model from unmet clinical needs. Aimed at students, researchers and professionals seeking to build careers in healthcare innovation, technology transfer or consulting.

3Health Investment Portal
CategoryPlatform/Directory
Description

An online portal connecting academic projects and startups from across Catalonia that are seeking investment, licensing or co-development agreements with investors, corporates and technology transfer offices. Open to investors, corporates, TTOs and startups globally.

4The Investment Readiness Series
CategoryProgram
Description

A program that facilitates meetings between research project managers and investors, targeting companies and research entities with projects ready to receive investment.

5ATMP Catalonia (Advanced Therapies Hub of Catalonia)
CategoryNetwork/Hub
Description

A coordinated hub of companies and entities working on advanced and emerging therapies (ATMPs) to position Catalonia as a global reference hub. Facilitates technology transfer, knowledge sharing, collaboration among R&D groups, and promotion of public-private partnerships.

6ATMP Catalyst
CategoryAcceleration Program
Description

A structured three-year acceleration program supporting early-stage projects and startups in advanced therapies to advance science and empower startups in transforming healthcare.

7INNOPASS
CategoryProgram/Open Call
Description

A semi-annual open call selecting innovations developed in the BioRegion of Catalonia that contribute to healthcare system transformation. Awards an 'Innovation Passport' to solutions with high maturity and strong clinical, organizational, social or environmental impact potential, and provides one year of personalized support.

8PASS (Catalan Health System Innovation Access Program)
CategoryProgram/Platform
Description

A comprehensive program that coordinates innovation access to the Catalan Health System. Includes an innovation platform, a tools and programs navigator, and a support unit that runs cohorts of selected startups with personalized scientific, technological and strategic guidance.

9Innovation Platform (Health Innovation Communities)
CategoryPlatform
Description

A directory-format platform featuring innovations candidates to access the Catalan Health System, facilitating interaction and connection among healthcare system stakeholders, solution providers and assessment bodies.

10Tools and Programs Navigator
CategoryPlatform/Catalog
Description

A comprehensive catalog of resources, programs and opportunities available to the innovation community in Catalonia, including acceleration programs, funding opportunities, validation services and regulatory support.

11PRECISEU
CategoryEuropean Project
Description

A European project coordinated by Biocat that strengthens collaboration between health innovation ecosystems and actors across Europe to share knowledge, scale solutions and drive transformation toward personalized and digital health models.

12BioRegion of Catalonia Report
CategoryPublication/Intelligence Report
Description

The most comprehensive analysis of assets, achievements and trends in the life sciences and healthcare sector in Catalonia, published annually since 2009. Provides official indicators on the evolution of the healthcare innovation ecosystem.

13Catalonia Life Sciences Database
CategoryDirectory/Database
Description

A comprehensive database of the BioRegion of Catalonia providing strategic information about companies, research institutions and stakeholders in the life sciences and healthcare ecosystem.

14Health Innovation Communities
CategoryPlatform
Description

An online platform facilitating connection and collaboration among health innovation stakeholders in the BioRegion of Catalonia, hosting the PASS Support Unit and community interactions.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1ACCIÓ (Government of Catalonia)
Strategic tierSupportingTypeOthersAnnounced on2025-01-01
Description

ACCIÓ is the agency for business competitiveness of the Government of Catalonia that supports the internationalization of companies. Biocat collaborates with ACCIÓ as an agent for supporting internationalization of the BioRegion ecosystem.

biocat.cat
2Catalan Ministry of Health (Departament de Salut)
Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

Co-leads the PASS (Catalan Health System Innovation Access Program) with CatSalut, AQuAS, and Biocat. Charged Biocat with coordinating the expert subcommittee that drafted the action plan to streamline innovation adoption in the healthcare system.

biocat.cat
Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

CatSalut is working on defining and specifying processes for innovation entry into SISCAT, including the new Programme for the Harmonised Adoption of Innovation in Healthcare (PAHISA). Co-leads PASS with Biocat.

Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

AQuAS is working on evaluation of health technologies and self-assessment tools to guide innovators in demonstrating value prior to adoption. Co-leads PASS with Biocat, CatSalut, and the Departament de Salut.

5Catalonia.BioHealth (Catalonia.Health)
Strategic tierSupportingTypeOthersAnnounced on2025-01-01
Description

An association representing healthcare and life sciences companies in Catalonia. Represented on Biocat's Board of Trustees, contributing industry perspective to the foundation's governance.

biocat.cat
Strategic tierSupportingTypeOthersAnnounced on2025-01-01
Description

The Spanish pharmaceutical industry association, represented on Biocat's Board of Trustees with multiple members including representatives from Amgen, AstraZeneca, Almirall, Laboratorios Ern, and Sanofi-Aventis.

Strategic tierSupportingTypeOthersAnnounced on2025-01-01
Description

The Spanish federation of healthcare technology companies in Catalonia, represented on Biocat's Board of Trustees through representatives from HARTMANN Group and Avinent Group.

8PRECISEU (EU-funded project)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

PRECISEU is a European project coordinated by Biocat that strengthens collaboration between health innovation ecosystems and actors across Europe to share knowledge, scale solutions, and drive transformation of health systems toward more personalized and digital models. It connects ecosystems and promotes adoption of personalized medicine.

biocat.cat
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Between 2014 and 2023, over 200 organizations and companies in the BioRegion participated in 1,198 collaborative research and innovation projects under Horizon 2020 and Horizon Europe programs, with collaborations in 88 countries and mobilizing €3.77 billion in resources.

10Xarxa de Parcs Científics i Tecnològics de Catalunya
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

The network of science and technology parks of Catalonia, represented on Biocat's Board of Trustees through the Director of Parc Científic de Barcelona.

biocat.cat
11Associació Catalana d'Entitats de Recerca (ACER)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Represented on Biocat's Board of Trustees through the Director of the Institute for Research in Biomedicine (IRB Barcelona).

biocat.cat
Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

AstraZeneca made a strategic commitment to the BioRegion including a major investment hub. Between 2021 and 2025, FDI totalled €2.382 billion with AstraZeneca's commitment playing a key role, generating 5,567 new jobs.

13Government of Catalonia
Strategic tierCoreTypeOthersAnnounced on2006-01-01
Description

Co-founding partner of Biocat along with Barcelona City Council. Represents the public sector stakeholders in the foundation's governance, including multiple ministries (Health, Economy, Research, Business, Agriculture) on the Board of Trustees.

biocat.cat
Strategic tierCoreTypeOthersAnnounced on2006-01-01
Description

Co-founding partner of Biocat along with the Government of Catalonia, establishing Biocat as a public-private foundation since 2006.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

EIT Health is a European-wide public-private partnership (Knowledge and Innovation Community) under Horizon Europe that coordinates health innovation across Europe. Broader in geographic scope than Biocat, with overlap on acceleration programs and healthcare-system transformation objectives pursued by Biocat via PRECISEU.

TypeDirect peer
Description

Medicon Valley Alliance is the life sciences cluster organization bridging Denmark and Sweden, focused on the greater Copenhagen-Skåne region. It is a direct functional peer to Biocat, running networking, investment-matching, and policy advocacy for life sciences stakeholders.

TypeDirect peer
Description

BIOCOM is the California-based life sciences association supporting San Diego and California life sciences companies through networking, capital access, and public policy advocacy, similar to Biocat's mandate for Catalonia.

TypeDirect peer
Description

Lyonbiopôle is the French competitive cluster dedicated to health and life sciences in the Auvergne-Rhône-Alpes region. Comparable to Biocat as a regional innovation cluster coordinating industry, research, and healthcare system stakeholders.

TypeDirect peer
Description

BioAlps is the life sciences cluster organization for Western Switzerland, based in Geneva. It performs an ecosystem coordination role analogous to Biocat, including networking, acceleration support, and promotion of regional life sciences activity on an international stage.

TypeDirect peer
Description

One Nucleus is the life sciences and healthcare cluster organization for the Cambridge-London corridor in the UK. It operates similarly to Biocat as a not-for-profit membership body driving deal flow, internationalization, and talent development for life sciences companies.

TypeDirect peer
Description

flanders.health is the Flemish life sciences cluster organization coordinating biotech, medtech, and pharma stakeholders in Belgium. Comparable to Biocat in operating model, member base, and emphasis on accelerating innovation access to healthcare systems.

TypeDirect peer
Description

Clust-ER Health is the health cluster of the Emilia-Romagna region in Italy, part of the regional innovation ecosystem coordination model. Functions as a peer to Biocat in coordinating regional life sciences stakeholders and supporting industry-academia collaboration within a public-private framework.

TypeDirect peer
Description

MassBio is the trade association and innovation cluster organization for Massachusetts' life sciences industry, coordinating industry, academia, and government. It is the closest international analogue to Biocat in scope, governance, and program offering, though it operates at significantly larger scale in a US context.

TypeDirect peer
Description

BioM is the cluster management organization for the biotechnology sector in Bavaria, Germany. Like Biocat, it coordinates research-to-market activities, runs acceleration programs, and connects startups with pharma and investors, making it a direct regional cluster peer within the European life sciences ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocat

Life Sciences Innovation Ecosystem Coordinationbiocat.cat

Biocat is the public-private foundation coordinating Catalonia's life sciences and healthcare innovation ecosystem, serving startups, research institutions, investors, corporates, and the Catalan Health System through acceleration programs, investment matching platforms, and adoption programs.

What Biocat does

Biocat (legal name: Biocat, la Fundació BioRegió de Catalunya) is a public-private foundation established in 2006 at the initiative of the Government of Catalonia and Barcelona City Council, headquartered at the Parc Científic de Barcelona. It functions as the official cluster coordinator for Catalonia's life sciences and healthcare innovation ecosystem — known as the BioRegion of Catalonia — rather than as a product company. Biocat does not develop proprietary technology products; instead, its core activity is orchestrating innovation across the ecosystem through a portfolio of interconnected programs and digital platforms, including acceleration programs (CRAASH Barcelona, ATMP Catalyst), training programs (d·HEALTH Barcelona), the Health Investment Portal connecting startups with investors, the PASS program for healthcare system adoption, the ATMP Catalonia advanced therapies hub, and the European PRECISEU project on personalized medicine. It also publishes the annual BioRegion Report, the authoritative intelligence source for the sector.

Biocat serves five primary stakeholder segments: startups and spin-offs in biotech, medtech, digital health, and advanced therapies; research institutions and universities; domestic and international investors and corporate venture arms (e.g., Ysios, Asabys, Novartis, Roche, Sanofi, Werfen); the Catalan Health System (SISCAT) through CatSalut, AQuAS, and the Ministry of Health; and large corporates seeking partnership and licensing opportunities. All core programs and services are provided free of charge to participants, with operations funded through institutional grants, public funding programs, and trustee support. Governance is shared: the Board of Trustees includes ministers from the Government of Catalonia alongside representatives from pharmaceutical companies, industry associations (Farmaindustria, Fenin Catalunya, Catalonia.Health), research institutions, and venture capital firms, with the President of the Government of Catalonia serving as Chairman.

The organization has approximately 11–50 employees led by CEO Robert Fabregat and a director team covering strategy, marketing, finance, acceleration, and scale-up. Its reach extends across 1,650 companies, 94 research institutions, 464 active startups, and 80+ investment firms operating in the BioRegion, with the broader sector representing 7.6% of Catalonia's GDP, €48.691 billion in turnover, and €9.165 billion in healthcare exports (45.7% of Spain's national total).

Biocat firmographics

Firmographics
Name
Biocat
Legal name
Biocat, la Fundació BioRegió de Catalunya
Website
https://biocat.cat
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Biocat is the public-private foundation coordinating Catalonia's life sciences and healthcare innovation ecosystem, serving startups, research institutions, investors, corporates, and the Catalan Health System through acceleration programs, investment matching platforms, and adoption programs.
Ownership category
akta.pro rank

Where Biocat is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Biocat business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Institutional / Public Funding: Biocat operates as a public-private foundation established in 2006 at the initiative of the Government of Catalonia and Barcelona City Council. It is funded through institutional grants, public funding programs, and membership/support from private-sector trustees. The foundation does not charge for its core programs and services.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Biocat product offering

Product offering

Core offering

Biocat is a public-private foundation that coordinates the life sciences and healthcare innovation ecosystem of Catalonia by running acceleration programs (CRAASH Barcelona, d·HEALTH Barcelona, ATMP Catalyst), investment matchmaking via the Health Investment Portal, healthcare-system adoption programs (PASS, INNOPASS), the ATMP Catalonia advanced-therapies hub, European project coordination (PRECISEU), and ecosystem intelligence (BioRegion of Catalonia Report). All programs and services are offered free of charge to entrepreneurs, researchers, investors, corporates, and the Catalan Health System.

Product overview

Biocat functions as a public-private foundation that coordinates and accelerates the life sciences and healthcare innovation ecosystem in Catalonia, rather than as a single product company. Its offering consists of multiple interconnected programs and platforms: acceleration programs (CRAASH Barcelona, d·HEALTH Barcelona, ATMP Catalyst) that support entrepreneurs and researchers; the Health Investment Portal connecting startups with investors; the ATMP Catalonia hub for advanced therapies; and the PASS (Catalan Health System Innovation Access Program) comprising an Innovation Platform, Tools and Programs Navigator, and Support Unit to facilitate healthcare innovation adoption. Additionally, Biocat coordinates European projects like PRECISEU and publishes the BioRegion of Catalonia Report as the official intelligence source for the ecosystem. The programs and platforms work together to support the full innovation lifecycle from research to market adoption and investment.

Differentiator

Problem solved

Functional benefit

Brands

  • ATMP Catalonia: The Advanced Therapies Hub of Catalonia, coordinated by Biocat, which drives research, manufacturing and development of advanced and emerging therapies to position Catalonia as a global benchmark hub.
  • PASS (Catalan Health System Innovation Access Program)
  • CRAASH Barcelona
  • d·HEALTH Barcelona

Products and services

  • CRAASH Barcelona A three-month acceleration program (currently in its 9th edition) that validates and brings to market innovations in medical devices, diagnostics, and digital health. Targeted at research teams and entrepreneurs established in or linked to Catalonia with high-potential projects.
  • d·HEALTH Barcelona A training program (currently in its 11th edition) that provides tools to learn how to innovate and develop a business model from unmet clinical needs. Aimed at students, researchers and professionals seeking to build careers in healthcare innovation, technology transfer or consulting.
  • Health Investment Portal An online portal connecting academic projects and startups from across Catalonia that are seeking investment, licensing or co-development agreements with investors, corporates and technology transfer offices. Open to investors, corporates, TTOs and startups globally.
  • The Investment Readiness Series A program that facilitates meetings between research project managers and investors, targeting companies and research entities with projects ready to receive investment.
  • ATMP Catalonia (Advanced Therapies Hub of Catalonia) A coordinated hub of companies and entities working on advanced and emerging therapies (ATMPs) to position Catalonia as a global reference hub. Facilitates technology transfer, knowledge sharing, collaboration among R&D groups, and promotion of public-private partnerships.
  • ATMP Catalyst A structured three-year acceleration program supporting early-stage projects and startups in advanced therapies to advance science and empower startups in transforming healthcare.
  • INNOPASS A semi-annual open call selecting innovations developed in the BioRegion of Catalonia that contribute to healthcare system transformation. Awards an 'Innovation Passport' to solutions with high maturity and strong clinical, organizational, social or environmental impact potential, and provides one year of personalized support.
  • PASS (Catalan Health System Innovation Access Program) A comprehensive program that coordinates innovation access to the Catalan Health System. Includes an innovation platform, a tools and programs navigator, and a support unit that runs cohorts of selected startups with personalized scientific, technological and strategic guidance.
  • Innovation Platform (Health Innovation Communities) A directory-format platform featuring innovations candidates to access the Catalan Health System, facilitating interaction and connection among healthcare system stakeholders, solution providers and assessment bodies.
  • Tools and Programs Navigator A comprehensive catalog of resources, programs and opportunities available to the innovation community in Catalonia, including acceleration programs, funding opportunities, validation services and regulatory support.
  • PRECISEU A European project coordinated by Biocat that strengthens collaboration between health innovation ecosystems and actors across Europe to share knowledge, scale solutions and drive transformation toward personalized and digital health models.
  • BioRegion of Catalonia Report The most comprehensive analysis of assets, achievements and trends in the life sciences and healthcare sector in Catalonia, published annually since 2009. Provides official indicators on the evolution of the healthcare innovation ecosystem.
  • Catalonia Life Sciences Database A comprehensive database of the BioRegion of Catalonia providing strategic information about companies, research institutions and stakeholders in the life sciences and healthcare ecosystem.
  • Health Innovation Communities An online platform facilitating connection and collaboration among health innovation stakeholders in the BioRegion of Catalonia, hosting the PASS Support Unit and community interactions.

Quantifiable outcome

  • €517 million in startup and scaleup investment raised in 2025, a historic record (+43% vs. 2024)
  • +3 more outcomes

Companies that use Biocat

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Biocat technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biocat partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered supporting and core.

  • ACCIÓ (Government of Catalonia)supportingOthers · 1 January 2025ACCIÓ is the agency for business competitiveness of the Government of Catalonia that supports the internationalization of companies. Biocat collaborates with ACCIÓ as an agent for supporting internationalization of the BioRegion ecosystem.
  • Catalan Ministry of Health (Departament de Salut)coreOthers · 1 January 2025Co-leads the PASS (Catalan Health System Innovation Access Program) with CatSalut, AQuAS, and Biocat. Charged Biocat with coordinating the expert subcommittee that drafted the action plan to streamline innovation adoption in the healthcare system.
  • Servei Català de la Salut (CatSalut)coreOthers · 1 January 2025CatSalut is working on defining and specifying processes for innovation entry into SISCAT, including the new Programme for the Harmonised Adoption of Innovation in Healthcare (PAHISA). Co-leads PASS with Biocat.
  • Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)coreOthers · 1 January 2025AQuAS is working on evaluation of health technologies and self-assessment tools to guide innovators in demonstrating value prior to adoption. Co-leads PASS with Biocat, CatSalut, and the Departament de Salut.
  • Catalonia.BioHealth (Catalonia.Health)supportingOthers · 1 January 2025An association representing healthcare and life sciences companies in Catalonia. Represented on Biocat's Board of Trustees, contributing industry perspective to the foundation's governance.
  • FarmaindustriasupportingOthers · 1 January 2025The Spanish pharmaceutical industry association, represented on Biocat's Board of Trustees with multiple members including representatives from Amgen, AstraZeneca, Almirall, Laboratorios Ern, and Sanofi-Aventis.
  • Fenin CatalunyasupportingOthers · 1 January 2025The Spanish federation of healthcare technology companies in Catalonia, represented on Biocat's Board of Trustees through representatives from HARTMANN Group and Avinent Group.
  • PRECISEU (EU-funded project)coreStrategic or Co-development Partner · 1 January 2025PRECISEU is a European project coordinated by Biocat that strengthens collaboration between health innovation ecosystems and actors across Europe to share knowledge, scale solutions, and drive transformation of health systems toward more personalized and digital models. It connects ecosystems and promotes adoption of personalized medicine.
  • Horizon Europe / Horizon 2020coreStrategic or Co-development Partner · 1 January 2025Between 2014 and 2023, over 200 organizations and companies in the BioRegion participated in 1,198 collaborative research and innovation projects under Horizon 2020 and Horizon Europe programs, with collaborations in 88 countries and mobilizing €3.77 billion in resources.
  • Xarxa de Parcs Científics i Tecnològics de CatalunyasupportingStrategic or Co-development Partner · 1 January 2025The network of science and technology parks of Catalonia, represented on Biocat's Board of Trustees through the Director of Parc Científic de Barcelona.
  • Associació Catalana d'Entitats de Recerca (ACER)supportingStrategic or Co-development Partner · 1 January 2025Represented on Biocat's Board of Trustees through the Director of the Institute for Research in Biomedicine (IRB Barcelona).
  • AstraZenecacoreOthers · 1 January 2025AstraZeneca made a strategic commitment to the BioRegion including a major investment hub. Between 2021 and 2025, FDI totalled €2.382 billion with AstraZeneca's commitment playing a key role, generating 5,567 new jobs.
  • Government of CataloniacoreOthers · 1 January 2006Co-founding partner of Biocat along with Barcelona City Council. Represents the public sector stakeholders in the foundation's governance, including multiple ministries (Health, Economy, Research, Business, Agriculture) on the Board of Trustees.
  • Barcelona City CouncilcoreOthers · 1 January 2006Co-founding partner of Biocat along with the Government of Catalonia, establishing Biocat as a public-private foundation since 2006.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Biocat competitors and assessment

Company assessment

Broad incumbents

  • EIT Health: EIT Health is a European-wide public-private partnership (Knowledge and Innovation Community) under Horizon Europe that coordinates health innovation across Europe. Broader in geographic scope than Biocat, with overlap on acceleration programs and healthcare-system transformation objectives pursued by Biocat via PRECISEU.

Direct peers

  • Medicon Valley Alliance: Medicon Valley Alliance is the life sciences cluster organization bridging Denmark and Sweden, focused on the greater Copenhagen-Skåne region. It is a direct functional peer to Biocat, running networking, investment-matching, and policy advocacy for life sciences stakeholders.
  • BIOCOM: BIOCOM is the California-based life sciences association supporting San Diego and California life sciences companies through networking, capital access, and public policy advocacy, similar to Biocat's mandate for Catalonia.
  • Lyonbiopôle: Lyonbiopôle is the French competitive cluster dedicated to health and life sciences in the Auvergne-Rhône-Alpes region. Comparable to Biocat as a regional innovation cluster coordinating industry, research, and healthcare system stakeholders.
  • BioAlps: BioAlps is the life sciences cluster organization for Western Switzerland, based in Geneva. It performs an ecosystem coordination role analogous to Biocat, including networking, acceleration support, and promotion of regional life sciences activity on an international stage.
  • One Nucleus: One Nucleus is the life sciences and healthcare cluster organization for the Cambridge-London corridor in the UK. It operates similarly to Biocat as a not-for-profit membership body driving deal flow, internationalization, and talent development for life sciences companies.
  • flanders.health (formerly FlandersBio): flanders.health is the Flemish life sciences cluster organization coordinating biotech, medtech, and pharma stakeholders in Belgium. Comparable to Biocat in operating model, member base, and emphasis on accelerating innovation access to healthcare systems.
  • Clust-ER Health (Emilia-Romagna): Clust-ER Health is the health cluster of the Emilia-Romagna region in Italy, part of the regional innovation ecosystem coordination model. Functions as a peer to Biocat in coordinating regional life sciences stakeholders and supporting industry-academia collaboration within a public-private framework.
  • Massachusetts Biotechnology Council (MassBio): MassBio is the trade association and innovation cluster organization for Massachusetts' life sciences industry, coordinating industry, academia, and government. It is the closest international analogue to Biocat in scope, governance, and program offering, though it operates at significantly larger scale in a US context.
  • BioM (Bavaria): BioM is the cluster management organization for the biotechnology sector in Bavaria, Germany. Like Biocat, it coordinates research-to-market activities, runs acceleration programs, and connects startups with pharma and investors, making it a direct regional cluster peer within the European life sciences ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

Biocat social profiles

Digital presence

Biocat financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocat leadership team

Management profile

Number of profiles

Profiles12 records

Biocat funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocat M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocat

What does Biocat do?

Biocat is a public-private foundation that coordinates the life sciences and healthcare innovation ecosystem of Catalonia by running acceleration programs (CRAASH Barcelona, d·HEALTH Barcelona, ATMP Catalyst), investment matchmaking via the Health Investment Portal, healthcare-system adoption programs (PASS, INNOPASS), the ATMP Catalonia advanced-therapies hub, European project coordination (PRECISEU), and ecosystem intelligence (BioRegion of Catalonia Report). All programs and services are offered free of charge to entrepreneurs, researchers, investors, corporates, and the Catalan Health System.

Is Biocat a public or private company?

Biocat is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Biocat founded?

Biocat was founded in 2006. It employs 11 to 50 people.

Where is Biocat based?

Biocat is headquartered in Barcelona, Spain, in the Europe region.

How does Biocat make money?

One revenue line is on record: institutional / Public Funding.

Who are Biocat's main competitors?

EIT Health is listed as a broad incumbent. Direct peers are Medicon Valley Alliance, BIOCOM, Lyonbiopôle, BioAlps, One Nucleus, flanders.health (formerly FlandersBio), Clust-ER Health (Emilia-Romagna), Massachusetts Biotechnology Council (MassBio) and BioM (Bavaria).

Does Biocat have an API?

No public API is recorded for Biocat.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MynewsdeskWHX Osaka Positions Osaka as a Global Hub for Healthy Longevity and Life Sciences InnovationWHX Osaka 2026, held from July 2-4, 2026, in Osaka, Japan, positioned the city as an emerging global hub for healthy longevity and life sciences innovation by bringing together international stakeholders from government, healthcare, academia, and industry to discuss future medicine and regenerative medicine. Governor Hirofumi Yoshimura highlighted Osaka's strengths in iPS cell technology and Nakanoshima Qross as a key innovation hub, emphasizing that healthy longevity represents both a human aspiration and a source of future industrial and economic growth. The event resulted in the signing of memoranda of understanding with four European regions—Friuli Venezia Giulia (Italy), Biocat (Catalonia), Lyonbiopole (France), and POM Limburg/Health Campus Limburg DC (Belgium)—to establish ongoing international partnerships under the "Osaka Vision for Healthy Longevity."Empresas de Capital Riesgo en EspaInvertir en Ciencia, organized by Xesgalicia and Unirisco, honors Centum and Biocat as leading benchmarks of technological innovation in EuropeThe Galician company Centum and the Catalan biotech ecosystem Biocat were honored at the Invertir en Ciencia Si es Rentable forum organized by Xesgalicia and Unirisco for their contributions to scientific entrepreneurship and innovation in Europe. Centum, specializing in aeronautical solutions for emergency, security, and defense applications, reported over 20 million euros in 2024 revenue with forecasts of approximately 50% growth in 2025. Biocat, which represents 8.7% of Catalonia's GDP, achieved a historic record of 347 million euros in startup investment in 2024.PR NewswireLes innovations précoces confortent une attitude positive lors de la conférence BIO-Europe Spring® 2017 à BarceloneThe 11th annual BIO-Europe Spring® 2017 conference concluded in Barcelona, Spain, drawing over 2,500 life sciences executives who participated in 15,070 one-to-one partnering meetings across 1,450 companies. The event, organized by EBD Group in collaboration with Biocat and the Government of Catalonia, featured a Startup Slam competition won by Peptomyc, whose CEO received free registration to BIO-Europe 2017 and mentorship from Johnson & Johnson Innovation. The next edition is scheduled for Amsterdam, Netherlands, in March 2018, to be sponsored by HollandBIO.PR NewswireInnovation im Frühstadium untermauert positive Prognose auf der BIO-Europe Spring® 2017 in BarcelonaThe BIO-Europe Spring 2017 conference concluded in Barcelona with over 2,500 executives participating in nearly 16,000 one-on-one meetings aimed at securing licensing opportunities. Organized by EBD Group and Biocat, the event highlighted early-stage innovation despite broader sector challenges, featuring a startup competition sponsored by Johnson & Johnson Innovation. The next iteration of the conference is scheduled for Amsterdam in March 2018.PR NewswireEarly Stage Innovation Underpins Positive Outlook at BIO-Europe Spring® 2017 in BarcelonaThe eleventh annual BIO-Europe Spring conference concluded in Barcelona, Spain, featuring over 2,500 attendees and nearly 15,000 one-to-one partnering meetings among 1,450 companies. The event highlighted early-stage innovation in the life sciences sector, with Biocat and Johnson & Johnson Innovation sponsoring key components like the Startup Slam. Organizers noted strong optimism in the international life science industry despite broader political and regulatory challenges.PR NewswireBIO-Europe Spring® 2017 va attirer des dirigeants du secteur pharmaceutique à la recherche de connaissances approfondies et de partenariats dans la biotechnologieThe 11th annual BIO-Europe Spring international partnering conference will take place in Barcelona, Spain from March 20–22, 2017 at the CCIB convention centre, organized by EBD Group and co-organized by Biocat. The event is expected to attract over 2,400 life sciences industry leaders from more than 1,400 companies, facilitating 12,500 face-to-face meetings and over 3,500 displayed licensing opportunities. The conference will feature opening remarks by executives from Intrexon Corporation and BeiGene, more than 120 company presentations, and educational sessions covering topics including early-stage oncology clinical trials, cell and gene therapy commercialization, and European biotech entrepreneurship.PR NewswireBIO-Europe Spring® 2017 versammelt Entscheidungsträger aus der Pharmaindustrie für Brancheneinblicke und Biotech-PartnerschaftenThe eleventh annual BIO-Europe Spring international partnering conference is being held March 20–22, 2017 at the CCIB Convention Centre in Barcelona, Spain, produced by EBD Group with Biocat as co-host.PR NewswireBIO-Europe Spring® 2017 to Draw Pharma Executives Seeking Industry Insight and Biotech PartnershipsThe eleventh annual BIO-Europe Spring international partnering conference will be held in Barcelona, Spain from March 20-22, 2017 at the CCIB Convention Centre, produced by EBD Group and co-hosted by Biocat. The conference is expected to draw more than 2,400 life sciences industry executives from over 1,400 companies and facilitate 12,500 one-to-one partnering meetings with 3,500+ posted licensing opportunities. The event will feature more than 120 company presentations and educational sessions covering topics including clinical trials, cell and gene therapies, R&D strategies, and immuno-oncology.PR NewswireBIO-Europe Spring® 2017 bringt innovative Biotech- und Pharmaunternehmen sowie Investoren für mögliche Partnerschaftsverträge nach BarcelonaEBD Group and Biocat announced the 11th annual BIO-Europe Spring 2017 international business partnering conference, scheduled for March 20-22, 2017 at the CCIB Convention Centre in Barcelona, Spain, expecting over 2,400 executives from more than 1,400 biotech, pharma, and investment firms. Catalonia's BioRegion, the co-host location, comprises 824 companies and attracted over 151 million euros in investments between 2015 and 2016, ranking fourth in Europe for biotech companies per capita. The conference will feature one-to-one partnering meetings organized through partneringONE, along with company presentations and networking opportunities for early-stage projects, startups, and mid-size pharma companies.PR NewswireBIO-Europe Spring® 2017 rassemblera à Barcelone des sociétés pharmaceutiques et biotechnologiques novatrices et des investisseurs en vue d'éventuels partenariatsThe 11th annual BIO-Europe Spring conference is scheduled to take place from March 20 to 22, 2017 at the CCIB Convention Centre Barcelona in Spain, produced by EBD Group in collaboration with Biocat. The event is expected to draw over 2,400 executives from more than 1,400 international biotech companies, pharmaceutical firms, and investors for facilitated one-on-one partnering meetings using EBD Group's partneringONE platform. The Catalonia BioRegion, which hosts the event, comprises 824 companies and attracted over €151 million in investment from 2015 to 2016.